Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren's syndrome

Rheumatology (United Kingdom)

Volumn 54, Issue 8, 2015, Pages 1429-1434

  Pontarini, Elena ^a   Fabris, Martina ^b   Quartuccio, Luca ^b   Cappeletti, Monica ^a,c   Calcaterra, Francesca ^a,c   Roberto, Alessandra ^a   Curcio, Francesco ^d   Mavilio, Domenico ^a,c   Della Bella, Silvia ^a,c   De Vita, Salvatore ^b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY HOSPITAL OF UDINE   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF UDINE   (Italy)

Author keywords

B lymphocytes; BAFF receptor; Belimumab; Sjogren's syndrome; Transitional B lymphocytes

Indexed keywords

B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR RECEPTOR; BELIMUMAB; CD27 ANTIGEN; IMMUNOGLOBULIN;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; BIOLOGICAL ACTIVITY; CELL EXPANSION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOGLOBULIN BLOOD LEVEL; MEMORY CELL; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SJOEGREN SYNDROME; TREATMENT DURATION; UPREGULATION;

EID: 84939499202     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev005     Document Type: Article

References (22)

1. Mavragani CP, Moutsopoulos HM. Sjogren's syndrome. Annu Rev Pathol 2014;9:273-85.
2. Baldini C, Pepe P, Quartuccio L et al. Primary Sjogren's syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients. Rheumatology 2014; 53:839-44.
3. Lazarus MN, Robinson D, Mak V, Moller H, Isenberg DA. Incidence of cancer in a cohort of patients with primary Sjogren's syndrome. Rheumatology 2006;45:1012-5.
4. Stohl W, Scholz JL, Cancro MP. Targeting BLyS in rheumatic disease: the sometimes-bumpy road from bench to bedside. Curr Opin Rheumatol 2011;23:305-10.
5. Mariette X, Roux S, Zhang J et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 2003;62:168-71.
6. Daridon C, Pers JO, Devauchelle V et al. Identification of transitional type II B cells in the salivary glands of patients with Sjogren's syndrome. Arthritis Rheum 2006;54: 2280-8.
7. De Vita S, Boiocchi M, Sorrentino D et al. Characterization of prelymphomatous stages of B cell lymphoproliferation in Sjogren's syndrome. Arthritis Rheum 1997;40:318-31.
8. Quartuccio L, Salvin S, Fabris M et al. BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology 2013;52: 276-81.
9. Mariette X, Seror R, Quartuccio L et al. Efficacy and safety of belimumab in primary Sjogren's syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis 2013, Advance access published 17 December 2013, doi: 10.1136/annrheumdis-2013-203991.
10. Vitali C, Bombardieri S, Jonsson R et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
11. Meiners PM, Arends S, Brouwer E et al. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjogren's syndrome treated with rituximab. Ann Rheum Dis 2012;71:1297-302.
12. Della Bella S, Taddeo A, Colombo E et al. Human herpesvirus-8 infection leads to expansion of the preimmune/natural effector B cell compartment. PLoS ONE 2010;5: e15029.
13. Bohnhorst JO, Bjorgan MB, Thoen JE, Natvig JB, Thompson KM. Bm1-Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjogren's syndrome. J Immunol 2001;167:3610-8.
14. Hansen A, Odendahl M, Reiter K et al. Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjogren's syndrome. Arthritis Rheum 2002;46:2160-71.
15. Sellam J, Miceli-Richard C, Gottenberg JE et al. Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjogren's syndrome and systemic lupus erythematosus. Ann Rheum Dis 2007;66:790-7.
16. Binard A, Le Pottier L, Devauchelle-Pensec V et al. Is the blood B-cell subset profile diagnostic for Sjogren syndrome? Ann Rheum Dis 2009;68:1447-52.
17. Pieper K, Grimbacher B, Eibel H. B-cell biology and development. J Allergy Clin Immunol 2013;131:959-71.
18. Palanichamy A, Barnard J, Zheng B et al. Novel human transitional B cell populations revealed by B cell depletion therapy. J Immunol 2009;182:5982-93.
19. Wei C, Anolik J, Cappione A et al. A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J Immunol 2007;178:6624-33.
20. Jacobi AM, Huang W, Wang T et al. Effect of longterm belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2010;62:201-10.
21. Kreuzaler M, Rauch M, Salzer U et al. Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors. J Immunol 2012;188: 497-503.
22. Lahiri A, Pochard P, Le Pottier L et al. The complexity of the BAFF TNF-family members: implications for autoimmunity. J Autoimmun 2012;39:189-98.